Company Monitoring Page for Roche

latest headlines for company on cafepharma

Samsung Bioepis first to secure EMA backing for Herceptin biosimilar
BioPharma Dive
Mon, 09/18/17 - 09:23 am
Tags:
Samsung Bioepis, EMA, Europe, biosimilars, Herceptin, Roche, breast cancer
FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths
Endpoints
Sat, 09/16/17 - 12:06 pm
Tags:
FDA, Roche, Keytruda, Tecentriq, clinical trials
Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
Motley Fool
Sat, 09/16/17 - 12:05 pm
Tags:
Halozyme, Inovalon, Teva Pharmaceutical, Unitedhealthcare Group, Roche, Bristol-Myers Squibb
FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin
Endpoints
Fri, 09/15/17 - 09:14 am
Tags:
FDA, Scott Gottlieb, Amgen, Allergan, biosimilars, Mvasi, Roche, Avastin
FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports
Fierce Pharma
Tue, 09/12/17 - 10:00 pm
Tags:
FDA, Tecentriq, Roche, bladder cancer, clinical trials
Roche gets hit with another big R&D setback as a prospective AMD blockbuster flops in PhIII
Endpoints
Sat, 09/9/17 - 02:14 pm
Tags:
Roche, R&D, AMD, lampalizumab
An accurate analysis of the differences between Swiss companies Roche and Novartis
GoInPharma
Sat, 09/9/17 - 01:22 pm
Tags:
Novartis, Roche, Switzerland
Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
Yahoo/Zacks.com
Sat, 09/2/17 - 11:11 am
Tags:
Parkinson's Disease, Novartis, Teva Pharmaceutial, UCB Pharma, MEDI1341, AstraZeneca, Takeda, PRX002, Prothena, Roche, Acorda, Inbrija, Adamas Pharmaceuticals, Gocovri
Best Pharma Stocks Based on R&D Spending
Motley Fool
Mon, 08/28/17 - 09:27 am
Tags:
R&D, pharma stocks, Roche, Novartis, Pfizer, JNJ, Merck
Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab
Endpoints
Thu, 08/24/17 - 09:53 am
Tags:
Shire, Roche, emicizumab, hemophilia A
Personal turf is ‘out,’ community workplaces are ‘in’ at the new Roche neighborhood
Endpoints
Mon, 08/21/17 - 11:24 am
Tags:
Roche, employees
An analysis of 2017 first half for pharmaceutical industry
GoInPharma
Sat, 08/19/17 - 10:51 am
Tags:
pharma industry, Pfizer, Sanofi, GSK, Roche, Celgene, Bristol-Myers Squibb
Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers
Fierce Pharma
Thu, 08/17/17 - 11:48 pm
Tags:
multiple sclerosis, MS, drug pricing, Bayer, Biogen, Merck KGaA, Novartis, Sanofi, Teva Pharmaceutical, Roche
Roche, Mimetas develop “gut-on-a-chip” tech for drug-testing
Drug Delivery Business News
Thu, 08/17/17 - 10:04 am
Tags:
Roche, Mimetas, drug development
New target could yield treatment for Alzheimer's, ALS and more
Fierce Biotech
Thu, 08/17/17 - 09:57 am
Tags:
Genentech, Roche, drug development, R&D, Alzheimer's disease, ALS
Drug developers face increasingly risky tightrope walk between top-line results and hard data
Endpoints
Tue, 08/15/17 - 10:57 am
Tags:
drug development, clinical trials, late stage data, Roche, Perjeta
Pharma's giants, new and old, tell more tales than their numbers show
Fierce Pharma
Fri, 08/11/17 - 11:16 am
Tags:
Big Pharma, JNJ, Pfizer, GSK, Roche, Novartis, Sanofi, Bristol-Myers Squibb
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
Thu, 08/10/17 - 06:58 pm
Tags:
pharma stocks, Merck, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, GSK, Roche, Sanofi, Bayer, Novo Nordisk, Celgene, Biogen, AstraZeneca
Dermira Commits $135M for Global Rights to Roche Eczema Drug
Xconomy
Tue, 08/8/17 - 11:15 pm
Tags:
Demira, Roche, eczema, lebrikizumab
As Roche wades biosimilar waters, more competitors circle Herceptin
BioPharma Dive
Wed, 08/2/17 - 09:28 pm
Tags:
Roche, Herceptin, biosimilars, Amgen, Allergan, ABP 980, Celltrion, CT-P6

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.